(hereafter labeled SCS) has resulted in significant pain reduction in many intractable PDPN patients. [9] [10] [11] However, in about 40% of these patients SCS treatment is not effective. [9] [10] [11] Conventional dorsal root ganglion stimulation (hereafter named DRGS) acts at the level of the dorsal root ganglion (DRG), a promising new location for neuromodulation in managing selected pain conditions-among those also PDPN. 12 DRGS enables the physician to target a more peripheral, selective communication station for all nociceptive signaling from the peripheral nervous system to the dorsal horn in the spinal cord, from where the information is further processed via the spinothalamic tracts to the brain. 13 The DRG plays an important role in both neuropathic and nociceptive pain conditions. 14 Therefore, while SCS can theoretically only modulate Aβ fiber signaling, DRGS might also be able to modulate Aδ-and C-type fiber signaling. 15 A key molecule in the processing and modulation of the nociceptive signal in the spinal dorsal horn is γ-aminobutyric acid (GABA). 16, 17 Experimental data demonstrated decreased extracellular GABA levels and increased intracellular GABA levels in the dorsal horn after peripheral nerve injury. 18, 19 GABA has been proposed to have a major role in nociceptive and non-nociceptive processing according to the Gate Control Theory. 20 Based on this, it was suggested to stimulate non-nociceptive Aβ fibers in the dorsal columns (SCS) aiming to turn on the Gate mechanisms and modulate the nociceptive input. In an experimental study of allodynic rats, increased levels of extracellular GABA were indeed found in the dorsal horns in response to SCS. 18, 21, 22 The pivotal role of GABA in the analgesic effect of SCS has furthermore been confirmed by the fact that the application of the GABA B agonist baclofen changed "non-responders-to-SCS" into "responders-to-SCS." [23] [24] [25] [26] The results of an experimental study of Janssen et al 27 demonstrated additionally that responders-to-SCS showed decreased levels of intracellular GABA-immunoreactivity (GABA-IR) in the spinal dorsal horn in comparison with non-responders-to-SCS and Sham-SCS animals. A relation between the release of intracellular accumulated GABA in the spinal cord dorsal horn, and the analgesic effect of SCS was therefore hypothesized. [27] [28] [29] [30] The mechanisms underlying DRGS and its ensuing pain relief are as yet unknown, and it is likely that it shares some spinal and supraspinal mechanisms with SCS, dependent on Aβ fibers activated by both types of stimulation. The present study is therefore aimed to investigate the hypothesis that DRGS induces GABA release from spinal dorsal horn cells. We used quantitative immunohistochemical analysis in an animal model of PDPN to study the effect of one single DRGS paradigm on the levels of spinal dorsal horn intracellular GABA.
| ME THODS

| Ethical statement
The protocols for this study were approved by the Animal Care 
| Animals
The study was performed on 48 adult female Sprague Dawley rats, weighing 170-230 g and 8 weeks old at the start of the experiments (Charles River, Maastricht, The Netherlands).They were preoperatively housed in pairs and postoperatively individually, in transparent plastic cages situated in a climate controlled room under a 12-hour light/dark cycle with food and water ad libitum. All efforts were made to minimize the number of animals used and their suffering, and alternatives to in vivo techniques were considered.
| Induction of diabetes mellitus
All animals fasted overnight before the induction of diabetes.
Streptozotocin (STZ, Sigma-Aldrich, Schnelldorf, Germany) was freshly dissolved in sterile NaCl 0.9% to a solution of 65 mg/mL. Animals were intraperitoneally injected with the STZ solution (65 mg/kg) to induce diabetes mellitus (DM). On day 4 post-STZ injection, blood glucose levels were measured from the saphenous vein, using an Accu-Chek Aviva® glucometer (Roche Diagnostics GmbH, Mannheim, Germany). Rats developing diabetes, defined as a blood glucose level of ≥15 mmol/L, 31 were included in the study.
| Development and assessment of mechanical hypersensitivity
Pain behavior was assessed by testing mechanical hypersensitivity based on the hind limb paw withdrawal response to Von Frey filaments (bending forces 0.6, 1.2, 2.0, 3.6, 5.5, 8.5, 15.1, and 28.84 g). Rats were placed in individual cages with a wire mesh floor and were allowed to acclimate to the experimental set-up for 15 minutes. The 50% withdrawal threshold (WT) was determined by use of the up-down method, 32 as previously described. 33 The cutoff value was defined as the absence of the paw withdrawal response to a 28.84 g force to prevent tissue damage. The registered 50% WT's (measured in grams) were then multiplied by 10 000 and logarithmically transformed to conform with Weber's law 34 and in order to obtain a linear scale.
Mechanical hypersensitivity was tested at baseline (pre-STZ injection) and weekly during 4 weeks post-STZ injection. Mechanical hypersensitivity, caused by PDPN, was defined to be present in case of a decrease in ≥0.2 unit of the log 10 (10 000 × 50% WT) when compared to baseline. Only animals that developed mechanical hypersensitivity were selected for this study and treated with DRGS.
| Implantation of DRGS electrode
Under general anesthesia, bipolar electrode was implanted unilaterally at the L5 DRG, according to the earlier described procedure adapted from Pan et al. 35, 36 In short, via a paravertebral incision the intervertebral foramen was exposed, the foramen was opened, and the anode and cathode were implanted at the DRG. The electrode was then secured into the transverse process followed by closure of the incision in layers.
| DRGS
For comparison with previous experimental studies regarding neurostimulation in PDPN animals, we used time and design as in previous (published) experiments. 33, 36 Animals were stimulated for 30 minutes at days 3 and 4 following implantation. The stimulation on day 3 was meant to establish the maximal pain relieving effect of DRGS, 36 while the stimulation on day 4 was performed to activate the mechanisms of action before perfusing the animals at the "peak On the third day following implantation, mechanical hypersensitivity was assessed pre-DRGS, during stimulation at t = 15 minutes and t = 30 minutes, and 30 minutes post-DRGS (t = 60 minutes). On the 4th day after implantation, rats received again 30 minutes of DRGS, just before being perfused (at the peak of the DRGS-induced pain relief). An animal was defined as a "responder-to-DRGS" if it developed an increase in the log 10 (10 000 × 50% WT) of ≥0.2 when compared to the pre-DRGS baseline. 36 
| Tissue preparation
| Immunohistochemical detection of GABA
Slides were allowed to dry at room temperature for 2 hour before being washed with Tris-buffered saline (TBS, 0.1 M, pH 7.6), including 0.3% Triton X-100 (TBS-T), TBS, and TBS-T. Thereafter, the slides were blocked for anti-GABA immunohistochemistry by the incubation in 2% normal donkey serum (Sigma-Aldrich, Zwijndrecht, The Netherlands, D9663) for 1 hour, diluted in TBS-T, and then incubated with rabbit anti-GABA polyclonal antibody (1:5000 diluted in TBS-T;
Sigma-Aldrich, Zwijndrecht, The Netherlands, A2052) for 48 hour.
After rinsing unbound primary antibody with TBS, sections were incubated for 2 hour with the secondary antibody Alexa fluor 488 donkey anti-rabbit IgG (1:100 diluted in TBS-T; Invitrogen, Breda, The Netherlands, A21206). Lastly, slides were rinsed with TBS and coverslipped with TBS/glycerol (20%/80%).
| Immunoreactivity analysis
After the GABA-staining protocol was completed, sections were observed under an Olympus AX-70 microscope and immunohistochemical analysis was performed, as previously described by Janssen et al. 27 Firstly, photomicrographs were taken from both ipsilateral and contralateral dorsal horns for the spinal levels L4-L6 using the Provis 
| Statistical analysis
The assay and the data analysis were performed in a blinded fashion in an identical mode as published before. 27 
| RE SULTS
| Description of cohorts of animals
Forty-three of the 48 animals (90%) that were injected with STZ developed DM (blood glucose ≥15 mmol/L). Twenty-two out of the 43 diabetic animals developed painful neuropathy (51%, ≥0.2 decrease in log 10 (10 000 × 50% WT) and were implanted with a DRGS system. Two animals were excluded from the study because of high MT (MT > 1mA) and two due to a connector breakage. Eleven animals were selected for treatment with DRGS and seven for treatment with Sham-DRGS. 36 Of these animals, 4 responders-to-DRGS animals and 4 Sham-DRGS animals were selected for the GABA-IR analyses.
| Development of PDPN and effect of DRGS on PDPN
In the DRGS group, the log 10 (10 000 × 50% WT) dropped significantly from 5.059 pre-STZ injection to 4.376 pre-DRGS (P < 0.01).
In the Sham-DRGS group, the log 10 (10 000 × 50% WT) dropped also significantly from 5.041 pre-STZ injection to 4.416 pre-Sham-DRGS (P < 0.05). 36 The mean log 10 (10 000 × 50% WT) value of the animals that were selected for GABA-IR analyses (n = 8) decreased from 4.99 ± 0.05 pre-STZ injection to 4.50 ± 0.06 pre-implantation (4 weeks post-STZ injection, P < 0.01). Motor thresholds were tested prior to DRGS (to select the appropriate amplitude). Normal responses were observed indicating no effect on motor behavior.
We described the efficacy of DRGS in an earlier publicized study. 36 In short, DRGS induced a complete reversal of mechanical hyper- 
| Comparison of mean gray values L4-L6
The anti-GABA immunohistochemical analysis showed a strong GABA-IR, prevalently in laminae 1-3 of the spinal dorsal horn with the Gate Control Theory, 18, 27 while our results instead point to a different mechanism involved in DRGS and its production of pain relief. The assay and data analysis utilized during our study were performed in an identical way as the previous study regarding GABA release in SCS, 27 with the difference that the previous study did not concern PDPN animals but neuropathic pain animals with a partial sciatic nerve ligation (according to the Seltzer model). From these data, it was concluded that the assay used for this study is sensitive enough to detect changes in GABA-IR in the spinal dorsal horn.
| Comparison of mean gray values per level
| D ISCUSS I ON
The dorsal horn is an essential and second-order relay station for the integration and modulation of pain. 16 The Gate Control Theory includes the pivotal role of inhibitory GABA-ergic interneurons modulating the nociceptive afferents and with this acts as the major regulatory component of the mechanism underlying SCS of dorsal columns. 16, [18] [19] [20] 27, 38 Electrical stimulation of the ascending branch of the non-nociceptive large Aβ fibers located in the dorsal column induces antidromic activation and generates synaptic interactions with GABA-ergic interneurons that inhibit the transmission of nociceptive signals entering the spinal dorsal horn via the slow-conducting C fibers. 16, 38 The GABA-ergic inhibitory interneurons in the superficial laminae of the dorsal horn can be activated by Aβ fiber inputs, which results in enhanced GABA release in the dorsal horn and an increase in extracellular GABA Janssen et al. 27 Peripheral nerve injury is known to induce a dysfunction of the natural GABAergic inhibition and a neuronal hyperexcitability in the spinal dorsal horn, which are among the major underlying causes of neuropathic pain. 18, 30, [39] [40] [41] The theory that nerve injury induces a loss in GABAergic inhibition in the spinal dorsal horn, causing neuropathic pain, is sustained by experimental studies that showed that pharmacological antagonism of GABA-ergic inhibition either via the GABA A, but mainly via the GABA B receptor in the spinal cord-induced mechanical hypersensivity. [42] [43] [44] Prior experimental studies confirm that SCS reduces the neuronal excitability and spinal pain transmission. 16 The role of GABA was furthermore substantiated by experimental and clinical studies demonstrating that the intrathecal application of GABA B receptor agonists like baclofen further potentiate the analgesic effects of SCS, [24] [25] [26] while at the same time local perfusion of GABA B receptor antagonists, like bicuculline, abolish this effect. 21 Therefore, analgesic effects of SCS may be especially attributed to the activation of the GABA B receptor. 21 Conventional SCS is not successful in all patients, and pain relieving effects can decline over the years. 9, 11 Lack of anatomic specificity of the painful area and positional variations in stimulation is furthermore well-known drawbacks of conventional SCS therapy. The DRG appears to be an appealing site for neurostimulation, 45 and clinical evidence indicates that DRGS provides efficacious pain relief in neuropathic pain sufferers, [46] [47] [48] [49] [50] which is confirmed by experimental studies. 35, 36 In comparison with SCS, DRGS has been demonstrated to have a better anatomic specificity of the painful area. 50 Furthermore, with DRGS the electrical fields have a direct effect on the neural tissues that are pathophysiologically involved in the chronic pain disease condition.
Since the location of stimulation is completely different with DRGS (local stimulation at the DRG) as compared to SCS (stimulation of the dorsal column), the question remains whether both stimulation paradigms act via the same mechanism. Our quantitative immunohistochemical data indicate that, even though DRGS and SCS resulted in a similar decrease in PDPN, 36 Clearly, DRGS does probably not only directly act via modulation of Aβ fibers, but also of Aδ-and C-type fibers. 15 As Aβ fibers are stimulated, one might expect that the analgesic effect of DRGS, like that of SCS, 27 is also linked to activation of intracellular GABA release in the dorsal horn. However, the results of the current study suggest that the analgesic effect of DRGS is not linked to GABA release in the dorsal horn. A hypothetical explanation for this could be that the modulation of a GABA-mediated Gate Control mechanism with DRGS actually takes place in a primary Gate for nociceptive control, namely at the DRG itself, instead of in the dorsal horn. This hypothesis is supported by a recently published experimental study of Du at al., 51 which confirmed that key components of the GABA-ergic transmission are expressed in the DRG. Their study showed that depolarizing stimuli induce GABA release in the DRG. Additionally, their study demonstrated a reduction in the neuronal excitability in the DRG in response to GABA. Furthermore, focal infusion of GABA or GABA reuptake inhibitors into the DRG alleviated neuropathic pain, and the delivery of GABA A receptor antagonists to the DRG on the other hand exacerbated peripherally induced nociception. 51 These results indicate that there is a endogenous GABA-ergic control in the DRG, 52, 53 and analgesic effects of focally applied GABA mimetics suggest that DRGS acts via the modulation of a GABA-mediated Gate Control at the level of the DRG.
In conclusion, DRGS does not induce GABA release in spinal dorsal horn of neuropathic (PDPN) rats. With this observation, we suggest that the mechanism underlying DRGS-induced pain relief is different from that of dorsal column SCS. Further research is warranted to elucidate the mechanism underlying DRGS in pain relief. The modulation of a GABA-mediated "Gate Control" in the DRG, functioning as a prime Gate of nociception, is suggested.
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